Superior molecularly altered influenza virus hemagglutinin peptide 308-317 inhibits collagen-induced arthritis by inducing CD4+ treg cell expansion

Arthritis and Rheumatism

Volumn 64, Issue 7, 2012, Pages 2158-2168

  Sun, Jian ^a   Li, Ru ^a   Guo, Jianping ^a   Jia, Yuan ^a   Sun, Xiaolin ^a   Liu, Yanying ^a   Li, Yingni ^a   Huang, Fangping ^b   Lu, Liwei ^c   Li, Zhanguo ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; GAMMA INTERFERON; INFLUENZA VIRUS HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ[308-317]; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TYROSYLALANYLLYSYLGLUTAMINYLALANYLTHREONYLLEUCYLALANYLLEUCYLALANINE; TYROSYLVALYLLYSYLGLUTAMINYLASPARAGINYLTHREONYLLEUCYLLYSYLLEUCYLALANINE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG MECHANISM; HISTOLOGY; MALE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN MODIFICATION; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; UPREGULATION; WILD TYPE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CELL PROLIFERATION; HEMAGGLUTININS, VIRAL; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; MALE; MICE; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 84863197516     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34372     Document Type: Article

References (41)

1. Monach PA, Benoist C, Mathis D. The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease [review]. Adv Immunol 2004;82:217-48. (Pubitemid 38209512)
2. VanderBorght A, Geusens P, Raus J, Stinissen P. The auto-immune pathogenesis of rheumatoid arthritis: role of autoreactive T cells and new immunotherapies. Semin Arthritis Rheum 2001; 31:160-75. (Pubitemid 33140642)
3. Firestein GS. Evolving concepts of rheumatoid arthritis [review]. Nature 2003;423:356-61. (Pubitemid 40852711)
4. H2 hypothesis of T cell-mediated tissue damage [review]. Nat Med 2007;13:139-45.
5. Kolls JK, Linden A. Interleukin-17 family members and inflammation [review]. Immunity 2004;21:467-76. (Pubitemid 39370503)
6. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004;50:650-9. (Pubitemid 38198849)
7. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-7. (Pubitemid 37467240)
8. Shevach EM. CD4+CD25+ suppressor T cells: more questions than answers [review]. Nat Rev Immunol 2002;2:389-400. (Pubitemid 37328746)
9. Morgan ME, Sutmuller RP, Witteveen HJ, van Duivenvoorde LM, Zanelli E, Melief CJ, et al. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum 2003;48:1452-60. (Pubitemid 36554546)
10. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004;200:277-85. (Pubitemid 39031247)
11. Londei M. Role of regulatory T cells in experimental arthritis and implications for clinical use. Arthritis Res Ther 2005;7:118-20. (Pubitemid 40775174)
12. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGF-β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-89. (Pubitemid 43214587)
13. H17 and regulatory T cells. Nature 2006;441:235-8.
14. Sekine T, Kato T, Masuko-Hongo K, Nakamura H, Yoshino S, Nishioka K, et al. Type II collagen is a target antigen of clonally expanded T cells in the synovium of patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:446-50. (Pubitemid 29317957)
15. Diab BY, Lambert NC, L'Faqihi FE, Loubet-Lescoulie P, de Preval C, Coppin H. Human collagen II peptide 256-271 preferentially binds to HLA-DR molecules associated with susceptibility to rheumatoid arthritis. Immunogenetics 1999;49:36-44. (Pubitemid 29039264)
16. Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC. X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. Immunity 1997;7: 473-81. (Pubitemid 27508699)
17. Rothbard JB, Busch R, Howland K, Bal V, Fenton C, Taylor WR, et al. Structural analysis of a peptide-HLA class II complex: identification of critical interactions for its formation and recognition by T cell receptor. Int Immunol 1989;1:479-86. (Pubitemid 19258080)
18. Xia L, Ru L, Zhanguo L. Altered influenza virus haemagglutinin peptides inhibit T cell responses to type II collagen in rheumatoid arthritis. Ann Rheum Dis 2005;64:1790-91. (Pubitemid 41667160)
19. Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 2005;12:167-81. (Pubitemid 41375640)
20. Myers LK, Rosloniec EF, Cremer MA, Kang AH. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 1997;61:1861-72.
21. Bayrak S, Holmdahl R, Travers P, Lauster R, Hesse M, Dolling R, et al. T cell response of I-Aq mice to self type II collagen: meshing of the binding motif of the I-Aq molecule with repetitive sequences results in autoreactivity to multiple epitopes. Int Immunol 1997;9:1687-99. (Pubitemid 27494132)
22. Kim WU, Lee WK, Ryoo JW, Kim SH, Kim J, Youn J, et al. Suppression of collagen-induced arthritis by single administration of poly(lactic-co-glycolic acid) nanoparticles entrapping type II collagen: a novel treatment strategy for induction of oral tolerance. Arthritis Rheum 2002;46:1109-20. (Pubitemid 34303826)
23. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003;48: 2670-81. (Pubitemid 37129445)
24. Bielekova B, Martin R. Antigen-specific immunomodulation via altered peptide ligands. J Mol Med 2001;79:552-65. (Pubitemid 32938383)
25. Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T, et al. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature 1996;379:343-6.
26. Santambrogio L, Lees MB, Sobel RA. Altered peptide ligand modulation of experimental allergic encephalomyelitis: immune responses within the CNS. J Neuroimmunol 1998;8:1-13. (Pubitemid 28248178)
27. Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 2002;51:2126-34. (Pubitemid 34729017)
28. Li R, Li X, Li Z. Altered collagen II 263-272 peptide immunization induces inhibition of collagen-induced arthritis through a shift toward Th2-type response. Tissue Antigens 2009;73:341-7.
29. Wakamatsu E, Matsumoto I, Yoshiga Y, Hayashi T, Goto D, Ito S, et al. Altered peptide ligands regulate type II collagen-induced arthritis in mice. Mod Rheumatol 2009;19:366-71.
30. Zhao J, Li R, He J, Shi J, Long Li, Li Z. Mucosal administration of an altered CII263-272 peptide inhibits collagen-induced arthritis by suppression of Th1/Th17 cells and expansion of regulatory T cells. Rheumatol Int 2008;29:9-16.
31. Li R, Li X, Li P, Yao ZQ, Guo JL, Li ZG. Effect of multiple amino acid substitutions of collagen II 263-272 on collagen-induced arthritis. Beijing Da Xue Xue Bao 2006;38:360-4. In Chinese.
32. Myers LK, Tang B, Rosloniec EF, Stuart JM, Chiang TM, Kang AH. Characterization of a peptide analog of a determinant of type II collagen that suppresses collagen-induced arthritis. J Immunol 1998;161:3589-95.
33. Skinner MA, Watson L, Geursen A, Tan PL. Lymphocyte responses to DR1/4 restricted peptides in rheumatoid arthritis. Ann Rheum Dis 1994;53:171-7. (Pubitemid 24123870)
34. Rosloniec EF, Whittington KB, Zaller DM, Kang AH. HLA-DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen. J Immunol 2002;168:253-9. (Pubitemid 34014125)
35. Garcia G, Komagata Y, Slavin AJ, Maron R, Weiner HL. Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen. J Autoimmun 1999;13:315-24.
36. Myers LK, Seyer JM, Stuart JM, Kang AH. Suppression of murine collagen-induced arthritis by nasal administration of collagen. Immunology 1997;90:161-4. (Pubitemid 27060542)
37. Koenders MI, Joosten LA, van den Berg WB. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006;65 Suppl III:iii29-33. (Pubitemid 44629098)
38. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21:467-76. (Pubitemid 39370503)
39. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis [review]. Nat Rev Immunol 2007;7:429-42. (Pubitemid 46834849)
40. Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008;105:7797-802. (Pubitemid 351872718)
41. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008;181:5396-404.